Signant Health Confirms Agreement to Acquire Digital Health Leader Ametris

Signant Health Confirms Acquisition of Ametris

Signant Health, an esteemed name in evidence generation for clinical studies, has made a notable move by entering into a definitive agreement to acquire Ametris, a provider of global digital health solutions. This announcement was made on April 16, 2026, and marks a significant step in Signant's commitment to enhancing its technological capabilities in the health sector.

For over two decades, Signant Health has established itself as a leader in leveraging sophisticated software and deep scientific expertise to collect and analyze data for clinical trials. The company has been trusted by over 600 sponsors, including all of the top 20 pharmaceutical companies, which speaks volumes about its reputation in the industry. In their pursuit of providing tailored solutions for clinical studies, Signant operates within various trial models, including traditional, virtual, and hybrid.

Ametris, formerly known as ActiGraph, specializes in digital health solutions. With this acquisition, Signant aims to integrate Ametris's innovative capabilities in digital health into its existing suite of services. While specific details regarding the transaction and how the combined offerings will manifest post-acquisition are still forthcoming, the overarching goal is clear: to create more comprehensive solutions for clinical studies that respond to the evolving needs of healthcare providers and patients alike.

This strategic move underscores Signant's intent to expand its footprint in the digital health landscape, which is increasingly crucial in modern clinical trial designs. The merger is expected to undergo standard regulatory processes and approvals, ensuring that all necessary compliance requirements are met before it is finalized.

As the digital health sector experiences rapid growth, driven by advancements in technology and an increasing focus on patient-centered care, Signant Health’s acquisition of Ametris positions it advantageously for future developments. Traditional clinical trials are being enhanced by digital solutions that facilitate remote patient monitoring, virtual consultations, and robust data analytics — capabilities that Ametris can provide.

Signant Health continues to emphasize its commitment to advancing clinical research through innovation and collaboration. With this new acquisition, the company is poised to enhance its offerings in measures such as remote electronic clinical outcome assessments (eCOA), electronic data capture (EDC), eConsent, and more — all fundamental components of efficient study execution and data integrity.

In joining forces with Ametris, Signant aims to redefine what is possible in the realm of clinical research. In a landscape where healthcare demands are becoming ever more complex, this acquisition reflects a forward-thinking approach to improving patient engagement, data quality, and overall trial efficiency.

Furthermore, with the expertise of both organizations combined, clients can expect a higher caliber of service and support throughout their clinical development programs. This merger is a testament to how Signant Health is evolving beyond traditional methodologies, adapting to a future where integrated digital solutions will play a critical role in clinical success.

As details surrounding the acquisition emerge, stakeholders across the industry will be looking closely at how this alignment will shape the future of clinical trials. Signant Health’s proactive approach towards integrating digital solutions signifies a pivotal shift in how clinical research will be conducted in the years to come.

For more information about Signant Health and the upcoming integration with Ametris, visit their official website at www.signanthealth.com.